Ignite Creation Date:
2024-07-17 @ 11:17 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06496308
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-07-03
Brief Title:
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Sponsor:
Ruijin Hospital
Organization:
Ruijin Hospital
Organization Data
Organization:
Ruijin Hospital
Class:
OTHER
Study ID:
ORDER
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Ruijin Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Zhao Weili
Responsible Party Title:
First Deputy Director Hematology Department
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Ruijin Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Third Xiangya Hospital of Central South University | UNKNOWN |
| Anhui Provincial Cancer Hospital | OTHER |
| Fujian Medical University Union Hospital | OTHER |
| Yantai Yuhuangding Hospital | OTHER |
| Huadong Hospital Affiliated with Fudan University Shanghai | UNKNOWN |
| The First Affiliated Hospital of Anhui Medical University | OTHER |
| Jiangxi Provincial Cancer Hospital | OTHER |
| Fujian Cancer Hospital | OTHER_GOV |